NVCR
NovoCure Limited
12.89
USD
This page is just a preview of the data found in TrendSpider’s full version
NovoCure Limited stock is up 6.88% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 13 Oct 17:09 | 17 Jan, 2025 | 22.50 | 43 | ||
| 23 Oct 14:15 | 17 Nov, 2023 | 15.00 | 366 | ||
| 25 Oct 19:55 | 15 Dec, 2023 | 12.50 | 656 | ||
| 26 Oct 16:11 | 19 Jan, 2024 | 12.50 | 6028 | ||
| 26 Oct 16:20 | 19 Jan, 2024 | 12.50 | 6028 | ||
| 09 Nov 15:41 | 17 Jan, 2025 | 25.00 | 169 | ||
| 16 Nov 14:47 | 15 Mar, 2024 | 10.00 | 13 | ||
| 17 Nov 19:04 | 17 Jan, 2025 | 10.00 | 4 | ||
| 17 Nov 20:17 | 15 Dec, 2023 | 15.00 | 953 | ||
| 17 Nov 20:21 | 15 Dec, 2023 | 12.50 | 900 |
NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.
